PolyGene as innovative biotech industry partner.
According to the EU secretary, Small and Medium-sized enterprises (SMEs) are the backbone of the economic future of the EU, and SMEs are main drivers of innovation in medicine.
Dynamic, flexible and keen to identify promising niches, SMEs are usually among the first to respond to emerging challenges and seize new market opportunities. Many engage in cutting-edge research.
Recognising this crucial contribution to the EU’s economy and to the excellence of its health research, the framework programmes have increasingly aimed to involve high-tech, research-intensive SMEs in collaborative research projects.
PolyGene actively contributes as an R&D intensive SME partner to EU projects (e.g., HORIZON 2020, Eurostars, IMI projects, etc.).
Networking is an essential factor for SMEs, and programmes like COST Actions are one of the possibilities allowing SMEs to get exchange knowledge and enhance biotechnological research.
It is crucial for the continued success of PolyGene to constantly increase and strengthen our relationship to academia, and therefore we are grateful for every lead that you might have to start networking.